论文部分内容阅读
本文介绍用旧结核茵素试验(OT)、链激酶-链道酶(SK-SD)试验、2,4硝基氯苯(DNCB)迟缓型超敏试验及麻疹血凝抑制试验作为免疫指标,对急性白血病患者共90例在化疗前、诱导缓解治疗期间、缓解后及巩固治疗时的细胞和体液免疫状态进行了估计。结果显示化疗前,部分病人免疫机能已处于抑制状态,在诱导缓解期,免疫机能与化疗前差异不大,表示小剂量的联合化疗对免疫机能无明显抑制作用。故认为在诱导缓解期温和的联合化疗与免疫疗法同时进行,并无矛盾。白血病病情对免疫状态的影响更大。
In this paper, we used immunodeficiency indicators such as OT, SK-SD, DNCB delayed hypersensitivity and measles hemagglutination inhibition, A total of 90 patients with acute leukemia were evaluated before chemotherapy, induction of remission, during remission and after consolidation therapy for cellular and humoral immune status. The results showed that before chemotherapy, some patients have been in the immune function was inhibited, in the induction of remission, immune function and chemotherapy before the difference was not significant, indicating that low-dose combination chemotherapy had no significant effect on immune function. Therefore, in the induction of remission mild combination chemotherapy and immunotherapy at the same time, there is no contradiction. Leukemia condition has a greater impact on the immune status.